.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,949,571

« Back to Dashboard
Patent 6,949,571 protects FYCOMPA and is included in two NDAs. There has been one Paragraph IV challenge on Fycompa.

This patent has forty-three patent family members in twenty-five countries.

Summary for Patent: 6,949,571

Title: 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Abstract:The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. ##STR1## In the formula, Q indicates NH, O or S; and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group or a group represented by the formula --X-A (wherein X indicates a single bond, an optionally substituted C.sub.1-6 alkylene group etc.; and A indicates an optionally substituted C.sub.6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
Inventor(s): Nagato; Satoshi (Chiba, JP), Ueno; Kohshi (Ibaraki, JP), Kawano; Koki (Ibaraki, JP), Norimine; Yoshihiko (Ibaraki, JP), Ito; Koichi (Chiba, JP), Hanada; Takahisa (Ibaraki, JP), Ueno; Masataka (Ibaraki, JP), Amino; Hiroyuki (Ibaraki, JP), Ogo; Makoto (Ibaraki, JP), Hatakeyama; Shinji (Ibaraki, JP), Groom; Anthony John (Wiltshire, GB), Rivers; Leanne (Kent, GB), Smith; Terence (Cambridgeshire, GB)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:10/296,719
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 23rd percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eisai Inc
FYCOMPA
perampanel
TABLET;ORAL202834-001Oct 22, 2012RXNo6,949,571► subscribeYY TREATMENT OF EPILEPSY
Eisai Inc
FYCOMPA
perampanel
TABLET;ORAL202834-002Oct 22, 2012RXNo6,949,571► subscribeYY TREATMENT OF EPILEPSY
Eisai Inc
FYCOMPA
perampanel
TABLET;ORAL202834-003Oct 22, 2012RXNo6,949,571► subscribeYY TREATMENT OF EPILEPSY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,949,571

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-175966Jun 12, 2000
United Kingdom0022483Sep 13, 2000
PCT Information
PCT FiledJune 08, 2001PCT Application Number:PCT/JP01/04857
PCT Publication Date:December 20, 2001PCT Publication Number: WO01/96308

Non-Orange Book Patents for Patent: 6,949,571

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,5491,2-dihydropyridine compounds, manufacturing method thereof and use thereof► subscribe
7,563,8111,2-dihydropyridine compounds, manufacturing method thereof and use thereof► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,949,571

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria420862► subscribe
Australia2001262723► subscribe
Australia6272301► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc